BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36398861)

  • 1. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
    Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
    Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.
    Pobbati AV; Han X; Hung AW; Weiguang S; Huda N; Chen GY; Kang C; Chia CS; Luo X; Hong W; Poulsen A
    Structure; 2015 Nov; 23(11):2076-86. PubMed ID: 26592798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 8. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
    Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
    Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
    Elife; 2022 Oct; 11():. PubMed ID: 36300789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
    Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
    ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of
    Tang TT; Konradi AW; Feng Y; Peng X; Ma M; Li J; Yu FX; Guan KL; Post L
    Mol Cancer Ther; 2021 Jun; 20(6):986-998. PubMed ID: 33850002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional analysis of the YAP-binding domain of human TEAD2.
    Tian W; Yu J; Tomchick DR; Pan D; Luo X
    Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7293-8. PubMed ID: 20368466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
    Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
    ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
    Mélin L; Abdullayev S; Fnaiche A; Vu V; González Suárez N; Zeng H; Szewczyk MM; Li F; Senisterra G; Allali-Hassani A; Chau I; Dong A; Woo S; Annabi B; Halabelian L; LaPlante SR; Vedadi M; Barsyte-Lovejoy D; Santhakumar V; Gagnon A
    ChemMedChem; 2021 Oct; 16(19):2982-3002. PubMed ID: 34164919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
    Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
    J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
    Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
    Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.